-
Cross-Cell-Line Machine Learning for Compound MoA
2026-09-28
Warchal and colleagues compared morphology-feature tree classification with image-based convolutional neural networks to predict compound mechanism of action across distinct breast cancer cell lines. Both approaches performed comparably within cell lines, but the tree classifier transferred more effectively to an unseen line, highlighting cell context as a central challenge for phenotypic profiling.
-
ISX-9 Boosts Circadian Amplitude Through BMAL1
2026-09-27
The study identifies ISX-9 as a small molecule that sustains circadian reporter amplitude and improves several daily physiological rhythms in middle-aged mice. Its proposed mechanism links calcium signaling and CaMKIIδ to phosphorylation-dependent activation of BMAL1, suggesting a route to strengthen circadian oscillations without deliberately shifting clock timing.
-
Bovine Insulin for Melanoma Metabolism Assays
2026-09-26
Use Bovine insulin as a controlled culture variable when testing how kinase inhibitors reshape melanoma-cell growth and metabolism—not as a substitute for the inhibitors or metabolic probes in the research. This practical guide pairs an insulin dose screen with ROS, PDH, and growth readouts, while flagging formulation and interpretation pitfalls.
-
RP3-340N1.2 Stabilizes IL-6 mRNA in NSCLC
2026-09-26
A 2026 study reports that the lncRNA RP3-340N1.2 supports non-small cell lung cancer cell proliferation and migration by limiting ZC3H12A-associated degradation of IL-6 mRNA. Knockdown reduced these tumor-associated phenotypes and affected macrophage polarization, providing a post-transcriptional mechanism to investigate in NSCLC models.
-
SmD2 Acetylation Links Splicing to PARP Sensitivity in HCC
2026-09-25
A 2024 study connects acetylation-dependent control of the spliceosome protein SmD2 with BRCA1/FANC alternative splicing, DNA-damage repair, and PARP-inhibitor response in hepatocellular carcinoma. It also reports that Romidepsin plus Olaparib has therapeutic potential in preclinical HCC models, suggesting a testable route to sensitize tumors through HDAC inhibition.
-
SARS-CoV-2 N Protein Sequesters GADD34 mRNA
2026-09-25
A 2024 study reports that SARS-CoV-2 nucleocapsid protein redirects GADD34 mRNA into atypical G3BP1-positive foci, reducing GADD34 expression and weakening IRF3-dependent interferon responses. The proposed mechanism connects stress-granule remodeling to innate immune evasion and provides specific molecular steps for further testing in infection models.
-
Fenipentol C8318: Assay Design and Evidence Limits
2026-09-24
A practical guide to using Fenipentol (SKU C8318) in cell-based experiments without confusing assay performance with biological activity. It covers compound identity, solvent and storage choices, evidence limits, and how to assess suppliers for gastrointestinal physiology studies.
-
Angiotensin 1/2 (5-7): Designing Better Assays
2026-09-24
Angiotensin 1/2 (5-7) is a sequence-defined renin–angiotensin system fragment with emerging relevance beyond cardiovascular research. Learn how to interpret its reported spike–receptor binding effects, choose controls, and distinguish biochemical binding from physiological or antiviral outcomes.
-
IWP-L6: Mapping Wnt Control to Assay Causality
2026-09-23
IWP-L6 is a potent Porcupine inhibitor for resolving how Wnt ligand production influences developmental and metabolic phenotypes. This article connects Porcn enzyme inhibition with assay timing, Wnt-driven osteoblast metabolism, and practical interpretation of pathway experiments.
-
2-NBDG Assay: From Uptake Signal to Mechanism
2026-09-22
The 2-NBDG Glucose Uptake Assay Kit enables non-radioactive, single-cell measurement of glucose transport and retention. This guide develops a decision framework for using uptake data alongside lipid-metabolism studies, including sorafenib-resistant hepatocellular carcinoma models.
-
Vidarabine Monohydrate: Assay Workflows
2026-09-22
Build reproducible antiviral experiments around Vidarabine monohydrate with DMSO-aware preparation, orthogonal viral readouts, and cytotoxicity controls. A staged screening framework inspired by interaction-assay research helps distinguish DNA replication interference from solvent, timing, or cell-health artifacts.
-
SmD2 Acetylation Links Splicing to PARP Response
2026-09-21
The reference study identifies SmD2 acetylation as a regulatory connection between core spliceosome function, BRCA1/FANC cassette exons, and DNA-damage repair in hepatocellular carcinoma. Its preclinical data support combining HDAC inhibition with Olaparib to increase PARP-inhibitor sensitivity, while also positioning SmD2 as a mechanistically informative biomarker and therapeutic target.
-
Developmental SSRI Exposure, Motivation, and MOR Signaling
2026-09-21
Cambre’s 2026 Columbia dissertation shows that developmental SSRI exposure produces persistent, motivation-specific reward deficits in adolescent and adult mice, while reward liking and learning remain comparatively preserved. Progressive-ratio performance improved after mu opioid receptor antagonism or nucleus accumbens MOR knockdown, identifying a reward-circuit mechanism that was not corrected by additional SSRI treatment or the MOR agonist tianeptine.
-
Novobiocin, DNA Replication, and Protoplast Morphogenesis
2026-09-20
The reference study shows that novobiocin links DNA replication with plasma membrane synthesis and vacuole formation in Enterococcus faecalis protoplasts. Its time-controlled inhibitor design provides a useful framework for separating replication-dependent morphogenesis from irreversible genomic damage.
-
Ginsenoside Rg6 Reverses Cisplatin Resistance in EOC
2026-09-19
The reference study identifies ginsenoside Rg6 as a potential adjunct for cisplatin-resistant epithelial ovarian cancer by linking reduced protein fucosylation to autophagy, CTR1 regulation, and inhibition of the GRB2–ERK1/2–mTOR axis. Its combination-focused design provides a mechanistic framework for studying how glycosylation and intracellular signaling jointly influence platinum response.